Skip to content

Study · Systematic review · n = 430 · 2026

3 results

Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.

Elganyny MKE, Elganyni AKE, Maskji HA, Ajaka N, Mishriki AES, Amin RSK, Abaza AOM, Elgokhy MM, Omair H, Esmaeil SFA, Abozaid HG, Elhagary AA, Ibrahim MM, El Ghafar MAA, Zidan MHS

La Clinica terapeutica1 Jul 2026

PMID42340790 (opens in a new tab)DOI10.7417/ct.2026.2083 (opens in a new tab)PepBankPUB-42340790
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of 3 studies of non-diabetic adults with obesity and CKD or hypertension, semaglutide significantly reduced BMI.

    In plain wordsIn non-diabetic adults with obesity and kidney disease or high blood pressure, studies found semaglutide lowered BMI.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction
    Study

    n = 430

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI reduction
    18.3%
    Tuttle
    BMI reduction
    11.8%
    Apperloo
    BMI reduction
    1.5%
    Vanek

    Source sentences

    Summary
    Semaglutide treatment significantly reduced BMI (mean reduction: Tuttle 18.3%, Apperloo 11.8%, Vanek 1.5%; P = 0.001)
    2 context sentences
    Summary · context
    A total of 580 studies were screened; 3 eligible studies (n=430 participants) were included.
    Summary · context
    Data were extracted from a randomized controlled trial, a real-world observational dialysis study, and a large post hoc trial analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of 3 studies of non-diabetic adults with obesity and CKD or hypertension, semaglutide improved hypertension control (SBP <130 mmHg).

    In plain wordsIn non-diabetic adults with obesity and kidney disease or high blood pressure, studies found more people reached good blood pressure control with semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion with SBP <130 mmHg
    Study

    n = 430

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    SBP <130 mmHg proportion
    20.6%
    Apperloo
    SBP <130 mmHg proportion
    12.5%
    Vanek
    SBP <130 mmHg proportion
    17.6%
    Tuttle

    Source sentences

    Summary
    improved hypertension control (SBP <130 mmHg: Apperloo 20.6%, Vanek 12.5%, Tuttle 17.6%; P < 0.02).
    2 context sentences
    Summary · context
    A total of 580 studies were screened; 3 eligible studies (n=430 participants) were included.
    Summary · context
    Data were extracted from a randomized controlled trial, a real-world observational dialysis study, and a large post hoc trial analysis.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of 3 studies of non-diabetic adults with obesity and CKD or hypertension, semaglutide improved renal function, with eGFR >30 increasing from baseline in all studies.

    In plain wordsIn non-diabetic adults with obesity and kidney disease or high blood pressure, studies found kidney function measures improved with semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseeGFR >30 ml/min/1.73m2 from baseline
    Study

    n = 430

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    eGFR >30 increase
    65.8%
    Apperloo
    eGFR >30 increase
    4.83%
    Vanek
    eGFR >30 increase
    36.4%
    Tuttle

    Source sentences

    Summary
    Renal function also improved, with eGFR >30 ml/min/1.73m² increasing from baseline in all studies (Apperloo 65.8%, Vanek 4.83%, Tuttle 36.4%; P < 0.001).
    2 context sentences
    Summary · context
    A total of 580 studies were screened; 3 eligible studies (n=430 participants) were included.
    Summary · context
    Data were extracted from a randomized controlled trial, a real-world observational dialysis study, and a large post hoc trial analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.